POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC

被引：0
|
作者：
Thomas, M. [1 ]
Grohe, C. [2 ]
Eberhardt, W. [3 ]
Rawluk, J. [4 ]
Reck, M. [5 ]
Laack, E. [6 ]
Wesseler, C. [7 ]
Rittmeyer, A. [8 ]
Alt, J. [9 ]
Reinmuth, N. [10 ]
Griesinger, F. [11 ]
Kern, J. [12 ]
机构：
[1] Univ Klinikum Heidelberg, Thoraxonkol, Thoraxklin, Heidelberg, Germany
[2] Evangel Lungenklin, Berlin, Germany
[3] Univ Klin, Essen, Germany
[4] Univ Klinikum, Freiburg, Germany
[5] LungenClin Grosshansdorf GmbH, Grosshansdorf, Germany
[6] Haematoonkol Hamburg, Hamburg, Germany
[7] Asklepios Klin Hamburg Harburg, Hamburg, Germany
[8] Fachklin Lungenerkrankungen, Immenhausen, Germany
[9] Univ Med, Mainz, Germany
[10] Asklepios Fachkliniken, Munich, Germany
[11] Pius Hosp, Oldenburg, Germany
[12] Klinikum Wurzburg Mitte Standort Missioklin gGmbH, Wurzburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P908
引用
收藏
页码：295 / 295
页数：1
相关论文
共 50 条
  • [1] POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
    Mok, T.
    Johnson, M.
    Garon, E.
    Peters, S.
    Soria, J.
    Wang, L.
    Jarkowski, A.
    Dennis, P.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1974 - S1974
  • [2] Durvalumab ± Tremelimumab plus Chemotherapy as First-line Therapy for metastatic NSCLC: Results of the Phase 3 POSEIDON Study
    Rawluk, J.
    Johnson, M. L.
    Cho, B. C.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S. L.
    Laktionov, K.
    Vasiliev, A.
    Kim, S. -W
    Ursol, G.
    Hussein, M.
    Lim, F. L.
    Yang, C. -T
    Araujo, L. H.
    Saito, H.
    Reinmuth, N.
    Shi, X.
    Poole, L.
    Medic, N.
    Peters, S.
    Garon, E.
    Mok, T. S. K.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 102 - 103
  • [3] First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
    Mok, Tony
    Schmid, Peter
    De Castro, Gilberto, Jr.
    Syrigos, Kostas
    Martin, Claudio
    Yamamoto, Nobuyuki
    Aren, Osvaldo
    Arrieta, Oscar
    Gottfried, Maya
    Jazieh, Abdul Rahman
    Ramlau, Rodryg
    Timcheva, Constanta
    Trani, Leonardo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1084 - S1084
  • [4] Durvalumab ± Tremelimumab plus Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
    Johnson, M.
    Cho, B. C.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S. L.
    Laktionov, K.
    Vasiliev, A.
    Trukhin, D.
    Kim, S.
    Ursol, G.
    Hussein, M.
    Lim, F.
    Yang, C.
    Araujo, L.
    Saito, H.
    Reinmuth, N.
    Shi, X.
    Poole, L.
    Peters, S.
    Garon, E.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S844 - S844
  • [5] Durvalumab ± tremelimumab plus chemotherapy as first-line treatment for mNSCLC: results from the Phase 3 POSEIDON study
    Kern, Jens
    Johnson, Melissa L.
    Cho, Byoung Chul
    Luft, Alexander
    Alatorre-Alexander, Jorge
    Geater, Sarayut Lucien
    Laktionov, Konstantin
    Vasiliev, Aleksandr
    Kim, Sang-We
    Ursol, Grygorii
    Hussein, Maen
    Lim, Farah Louise
    Yang, Cheng-Ta
    Araujo, Luiz Henrique
    Saito, Haruhiro
    Reinmuth, Niels
    Shi, Xiaojin
    Poole, Lynne
    Medic, Nenad
    Peters, Solange
    Garon, Edward B.
    Mok, Tony
    Thomas, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 146 - 146
  • [6] CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
    Paz-Ares, L.
    Jiang, H.
    Huang, Y.
    Dennis, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2398
  • [7] NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
    de Castro Jr, Gilberto
    Rizvi, Naiyer A.
    Schmid, Peter
    Syrigos, Konstantinos
    Martin, Claudio
    Yamamoto, Nobuyuki
    Cheng, Ying
    Moiseyenko, Vladimir
    Summers, Yvonne
    Vynnychenko, Ihor
    Lee, Sung Yong
    Bryl, Maciej
    Zer, Alona
    Erman, Mustafa
    Timcheva, Constanta
    Raja, Rajiv
    Naicker, Kirsha
    Scheuring, Urban
    Walker, Jill
    Mann, Helen
    Chand, Vikram
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 106 - 119
  • [8] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF TREMELIMUMAB plus DURVALUMAB plus CHEMOTHERAPY VS PEMBROLIZUMAB plus CHEMOTHERAPY AND NIVOLUMAB plus IPILIMUMAB plus CHEMOTHERAPY FOR FIRST-LINE METASTATIC NSCLC
    Johal, Sukhvinder
    Miranda, Miguel
    Sarbajna, Tina
    Shi, Xiaojin
    Greystoke, Alastair
    Johnson, Melissa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A608 - A608
  • [9] NEPTUNE China Cohort: First-Line Durvalumab plus Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
    Cheng, Y.
    Zhou, Q.
    Han, B.
    Fan, Y.
    Shan, L.
    Chang, J.
    Sun, S.
    Fang, J.
    Chen, Y.
    Sun, J.
    Wu, G.
    Mann, H.
    Naicker, K.
    Shire, N.
    Mok, T.
    De Castro, G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S358 - S358
  • [10] Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
    Gadgeel, Shirish
    Gandhi, Leena
    Borghaei, Hossein
    Socinski, Mark A.
    Gubens, Matthew A.
    Stevenson, James
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Papadimitrakopoulou, Vassiliki
    Bourque, Jennifer
    Bachman, Robert D.
    Ge, Joy Yang
    Im, Ellie
    Patnaik, Amita
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
12345